Seres Therapeutics (NASDAQ:MCRB) Shares Cross Below Two Hundred Day Moving Average - Time to Sell?

Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report) shares crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $14.41 and traded as low as $7.14. Seres Therapeutics shares last traded at $7.46, with a volume of 76,902 shares changing hands.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Chardan Capital restated a "neutral" rating and issued a $6.00 target price (up previously from $1.25) on shares of Seres Therapeutics in a report on Thursday, May 8th. The Goldman Sachs Group reduced their price target on shares of Seres Therapeutics from $20.00 to $15.00 and set a "sell" rating for the company in a research report on Friday, March 14th. Finally, StockNews.com raised Seres Therapeutics from a "sell" rating to a "hold" rating in a report on Friday, May 9th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat.com, Seres Therapeutics currently has an average rating of "Hold" and an average price target of $73.67.

Seres Therapeutics Stock Performance

The firm has a fifty day simple moving average of $10.81 and a two-hundred day simple moving average of $14.33. The firm has a market cap of $71.95 million, a PE ratio of -35.82 and a beta of 2.89.

Seres Therapeutics (NASDAQ:MCRB - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported ($2.24) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($1.57). Equities analysts forecast that Seres Therapeutics, Inc. will post -0.38 EPS for the current fiscal year.

Hedge Funds Weigh In On Seres Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of MCRB. Avantax Advisory Services Inc. grew its stake in shares of Seres Therapeutics by 170.9% during the fourth quarter. Avantax Advisory Services Inc. now owns 45,179 shares of the biotechnology company's stock worth $38,000 after acquiring an additional 28,500 shares during the last quarter. Jane Street Group LLC raised its holdings in shares of Seres Therapeutics by 181.4% in the fourth quarter. Jane Street Group LLC now owns 58,736 shares of the biotechnology company's stock worth $49,000 after buying an additional 37,866 shares during the last quarter. SBI Securities Co. Ltd. lifted its stake in shares of Seres Therapeutics by 221.8% during the first quarter. SBI Securities Co. Ltd. now owns 69,664 shares of the biotechnology company's stock worth $49,000 after buying an additional 48,013 shares during the period. Goldman Sachs Group Inc. increased its position in shares of Seres Therapeutics by 40.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 74,629 shares of the biotechnology company's stock valued at $52,000 after acquiring an additional 21,679 shares during the period. Finally, Invesco Ltd. raised its stake in Seres Therapeutics by 193.2% in the 1st quarter. Invesco Ltd. now owns 136,572 shares of the biotechnology company's stock worth $96,000 after acquiring an additional 89,995 shares during the last quarter. 59.34% of the stock is owned by hedge funds and other institutional investors.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.